Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Phase III Iclaprim trial results 'bode very well' for Motif Bio, says Northland Capital's Alexandre

Vadim Alexandre, head of research at Northland Capital Partners gives his view on Motif Bio Plc's (LON: MTFB, NASDAQ:MTFB) successful completion of a phase III clinical trial of its next-generation antibiotic, iclaprim.

The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections (ABSSSI).

''We know [Iclaprim] kills bacteria in the petri dish, we now know from this trial that it works in humans and we also know from a previous phase III trial ...  that it met its primary endpoint as well'', Alexandre says.

''There's very good reason to believe that the drug works and there's nothing in these results that are red flags to say that it shouldn't work in the second trial''.

 
Meet Rainbow Rare Earths Limited, Eurasia Mining plc, Mariana Resources Ltd., Anglo Asian Mining Plc and Hannan Metals Ltd at our event, London, 09 May 2017. Register here »
Why Invest In Motif Bio Plc? Read More Here

Register here to be notified of future Motif Bio Plc articles
View full MTFB profile

Motif Bio Plc Timeline

Article
November 24 2016

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use